Vima’s Hope: First Dystonia Patient Dosed in Phase 2 Study
Phase 1 data for VIM0423 showed the oral agent was safe and well tolerated through 28 days in healthy...
Jon Napitupulu
Sellas Launches Pioneering AML Trial, Enrolls First Patient
SELLAS’ CDK9 inhibitor SLS009 (tambiciclib) previously delivered a 33% overall response rate across evaluable relapsed/refractory AML patients, rising to...
Aplagon Announces Dosing in Phase 2a Ischemia Trial
Aplagon has dosed the first patient in HEALING, a Phase 2a study of APAC in chronic limb-threatening ischemia secondary...
c-bio Cleared for T-Cell Therapy Trial in Cervical Cancer
Cbio has received regulatory clearance to initiate a first‑in‑human Phase I/IIa study of novoleucel in persistent or recurrent cervical...
Phase 2b Tuberculosis Trial Doses First Patient with ALPE
Prior data on alpibectir-ethionamide (AlpE) showed a 7-day early bactericidal activity signal comparable to isoniazid and a generally acceptable...
New Gedatolisib Breast Cancer Data from VIKTORIA-1 Study
In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer post-CDK4/6 inhibitor, gedatolisib...
FDA Clears First-Ever Dental MRI After Successful Trial
FDA has cleared the first dental‑dedicated MRI system in the U.S., the MAGNETOM Free.Max Dental Edition, following a clinical...
Profound Medical to Discuss First CAPTAIN Trial Outcomes
No efficacy or safety figures were disclosed. Profound Medical will present the first clinical outcomes from CAPTAIN, a Level...
Bioversys’ New Tuberculosis Trial Results Published in NEJM
A 7-day Phase 2a early bactericidal activity study in pulmonary tuberculosis established clinical proof of concept for alpibectir plus...
ACTG LATITUDE Study Findings Published in New England Journal
Regimen failure through 48 weeks was 22.8% with long-acting cabotegravir plus rilpivirine versus 41.2% with continued daily oral ART...